Details for Patent: 12,661,407
Which drugs does patent 12,661,407 protect, and when does it expire?
Patent 12,661,407 protects ZILXI and is included in one NDA.
This patent has twenty-two patent family members in ten countries.
Summary for Patent: 12,661,407
| Title: | Compositions, gels and foams with rheology modulators and uses thereof |
| Abstract: | The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators. |
| Inventor(s): | Dov Tamarkin, Elana Gazal, Yohan HAZOT, David Schuz, Irakliy PAPIASHVILI |
| Assignee: | Foamix Ltd , Journey Medical Corp |
| Application Number: | US18/462,080 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 12,661,407
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | ZILXI | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 213690-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,661,407
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010302350 | ⤷ Start Trial | |||
| Australia | 2015224534 | ⤷ Start Trial | |||
| Brazil | 112012007473 | ⤷ Start Trial | |||
| Canada | 2776366 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
